JPRN-jRCTs021210077
Recruiting
未知
Exploratory study to evaluate the efficacy and safety of tocilizumab for Takayasu's arteritis based on classification by type of autoantibody - Exploratory study to evaluate the efficacy and safety of tocilizumab for Takayasu's arteritis based on classification by type of autoantibody
Ishii Tomonori0 sites20 target enrollmentMarch 22, 2022
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ishii Tomonori
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet all of the following conditions (1\) to (5\)
- •1\) Patients over 20 years old (at the time of consent)
- •2\) Patients diagnosed with Takayasu's arteritis according to any of the following criteria at the time of registration. It does not matter whether tocilizumab is used or not.
- •1\.2017 Ministry of Health, Labor and Welfare Takayasu's Arteritis Diagnostic Criteria
- •2\.American Rheumatology Society (ACR) ,Takayasu's Arteritis Diagnostic Criteria (1990\)
- •3\) Patients with no inflammatory findings of Takayasu's arteritis at the time of registration
- •4\) Patients whose steroid dose at the time of registration can be reduced to 20 mg / day or less in terms of prednisolone.
- •5\) Patients who can confirm the history of recurrence on the medical record under the administration of steroids with prednisolone equivalent of 7\.5 mg / day or more. It is assumed that any of the following is present as a necessary symptom or finding as a recurrence symptom.
- •Headache, dizziness, systemic symptoms (fever, malaise, weight loss, joint symptoms, muscle symptoms, etc.), vascular lesions and associated symptoms, CRP persistent positive
Exclusion Criteria
- •Check the following at the time of registration and exclude patients who fall under any of the following. Regarding the confirmation of the criteria corresponding to (4\) to (9\), If there is a clinical test result conducted within 4 weeks (28 days) before registration (Day 1\), even if it is a test performed before obtaining consent, it is possible to judge from the result.
- •1\) Patients who received new or increased doses of immunosuppressive agents other than steroids within 4 weeks (28 days) before registration
- •2\) Patients who received biologics other than tocilizumab and rituximab (anti\-TNF\-alpha preparation, abatacept, anti\-IL\-6 receptor preparation, etc.) within 3 months (12 weeks) before registration.
- •3\) Patients who received rituximab within 6 months (24 weeks) before enrollment
- •4\) Patients with severe renal impairment (nephrotic syndrome, serum creatinine of 2\.5 mg / dL or higher)
- •5\) Patients with severe liver dysfunction (child classification B or higher)
- •6\) Patients with severe cardiac dysfunction (ischemic heart disease, heart failure) or findings requiring treatment on electrocardiogram / echocardiography
- •7\) Patients with drug\-resistant hypertension
- •8\) Patients with malignant tumor or history of malignant tumor (excluding cases without recurrence for 5 years or more)
- •9\) HBsAg positive, HIV positive, HCV positive patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical ventilatioAcquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.MedDRA version: 20.0Level: PTClassification code 10077255Term: Intensive care unit acquired weaknessSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Not possible to specifyEUCTR2021-002329-56-ESSociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)200
Recruiting
Phase 2
Exploratory Study to Evaluate the Efficacy and Safety of Baricitinib in Interstitial Pneumonia Associated with Anti-MDA5 Antibody-Positive DermatomyositisInterstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositisJPRN-jRCTs031220641Fujio Keishi5
Not yet recruiting
Not Applicable
The exploratory study for the efficacy and the safety of Rikkunshito on symptoms of indigestion in the patients with Functional HeartburFunctional HeartburnJPRN-UMIN000029668ippon Medical School Graduate School of Medicine20
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Hangeshashinto on symptoms of heartburn /belch in the patients with gastroesophageal reflux disease (GERD)GERDJPRN-UMIN000021251Osaka Medical College80
Completed
Not Applicable
The exploratory study for the efficacy and the safety of Daikenchuto(TJ-100) on abdominal pain and abdominal fullness feeling in the patients with fecal incontinence.Abdominal pain and abdominal fullness feeling in the patients with fecal incontinenceJPRN-UMIN000030252Medical Corporation Seiaikai, Gion Usshita Hospital50